Our Publications
Below we provide links to posters and publications by Pharmetheus affiliates in chronological order.
Please note that access to some publications may require a subscription.
2023
Brooks L, Dolton M, Langenhorst J, Yoshida K, Lien YTK, Malhi V, Li C, Perez-Moreno P, Bond J, Chen YC, Yu J.
Concentration QTc Analysis of Giredestrant: Overcoming QT/heart rate Confounding in the Presence of Drug-Induced Heart Rate Changes
Pharmetheus Affiliates
2022
Tang F, Langenhorst J, Dang S, Kassir N, Owen R, Purdon B, Magnusson MO, Deng R.
Population Pharmacokinetics of Tenecteplase in Patients With Acute Myocardial Infarction and Application to Patients With Acute Ischemic Stroke
Pharmetheus Affiliates
Mats Magnusson, Ph.D.
Svensson RJ, Ooi QX, Friberg LE, Maharaj N, Reddy PK, López‐Lázaro L, Hansson E.
Rituximab pharmacokinetic and pharmacokinetic–pharmacodynamic evaluation based on a study in diffuse large B-cell lymphoma: Influence of tumor size on pharmacokinetic and assessment of pharmacokinetic similarity
Pharmetheus Affiliates
Derippe T, Fouliard S, Marchiq I, Dupouy S, Almena-Carrasco M, Geronimi J, Declèves X, Chenel M, Mager DE.
Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia
Pharmetheus Affiliates
Moein A, Lu T, Jönsson S, Ribbing J, Kassir N, Zhang W, Sperinde G, Zhang R, Tang M, Oh YS, Bruno R.
Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis
Pharmetheus Affiliates
Eckernäs E, Timmermann C, Carhart-Harris R, Röshammar D, Ashton M.
Population Pharmacokinetic/Pharmacodynamic Modeling of the Psychedelic Experience Induced by N,N-dimethyltryptamine - Implications for Dose Considerations
Pharmetheus Affiliates
Mitchell LG, Röshammar D, Huang F, Albisetti M, Brandão LR, Bomgaars L, Chalmers E, Halton J, Luciani M, Joseph D, Tartakovsky I.
Anticoagulant Effects of Dabigatran on Coagulation Laboratory Parameters in Pediatric Patients: Combined Data from Five Pediatric Clinical Trials
Pharmetheus Affiliates
Svensson RJ, Jonsson EN.
Efficient and relevant stepwise covariate model building for pharmacometrics
Pharmetheus Affiliates
Xiong W, Hietala SF, Nyberg J, Papasouliotis O, Johne A, Berghoff K, Goteti K, Dong J, Girard P, Venkatakrishnan K, Strotmann R.
Exposure–Response Analyses for the MET Inhibitor Tepotinib Including Patients in the Pivotal VISION Trial: Support for Dosage Recommendations
Pharmetheus Affiliates
Dubbelboer IR, Sjögren E.
Physiological Based Pharmacokinetic and Biopharmaceutics Modelling of Subcutaneously Administered Compounds – An Overview of In Silico Models
Pharmetheus Affiliates
Dubbelboer IR, Sjögren E.
Overview of Authorized Drug Products for Subcutaneous Administration: Pharmaceutical, Therapeutic, and Physicochemical Properties
Pharmetheus Affiliates
Jonsson EN, Nyberg J.
A Quantitative Approach to the Choice of Number of Samples for Percentile Estimation in Bootstrap and Visual Predictive Check Analyses
Pharmetheus Affiliates
Kotani N, Dolton M, Svensson RJ, Ribbing J, Friberg LE, Vadhavkar S, Cheung D, Staton T, Sperinde G, Jin J, Putnam WS, Quartino A.
Population Pharmacokinetics and Exposure-Response Relationships of Astegolimab in Patients with Severe Asthma
Pharmetheus Affiliates
Xiong W, Papasouliotis O, Jonsson EN, Strotmann R, Girard P.
Population Pharmacokinetic Analysis of Tepotinib, an Oral MET Kinase Inhibitor, Including Data From the VISION Study
Pharmetheus Affiliates
Tomita Y, Hansson E, Mazuir F, Wellhagen G, Ooi QX, Mezzalana E, Kitamura A, Nemoto D, Bolze S.
Imeglimin Population Pharmacokinetics and Dose Adjustment Predictions for Renal Impairment in Japanese and Western Patients with Type 2 Diabetes
Pharmetheus Affiliates
Meyer C, Dierick I, Gauderat G, Langenhorst J, Sarr C, Leroux E, Chenel M, Fouliard S, Passier P.
How to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an Example
Pharmetheus Affiliates
Bergstrand M, Hansson E, Delaey B, Callewaert F, Sousa RP, Sargentini-Maier ML.
Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura
Pharmetheus Affiliates
Eckernäs E, Timmermann C, Carhart-Harris R, Röshammar D, Ashton M.
N,N-dimethyltryptamine affects electroencephalography response in a concentration-dependent manner—A pharmacokinetic/pharmacodynamic analysis
Pharmetheus Affiliates
Yngman G, Bjugård Nyberg H, Nyberg J, Jonsson EN, Karlsson MO.
An Introduction to the Full Random Effects Model
Pharmetheus Affiliates
2021
Tosca EM, Gauderat G, Fouliard S, Burbridge M, Chenel M, Magni P.
Modeling Restoration of Gefitinib Efficacy by Co-Administration of MET Inhibitors in an EGFR Inhibitor-Resistant NSCLC Xenograft Model: A Tumor-in-Host DEB-Based Approach
Pharmetheus Affiliates
Moein A, Lu T, Jönsson S, Ribbing J, Kassir N, Zhang W, Zhang R, Tang M, Oh YS, Bruno R, Zhu R.
Population Pharmacokinetic Analysis of Etrolizumab in Patients with Moderately-to-Severely Active Ulcerative Colitis
Pharmetheus Affiliates
Kassir N, Zhu R, Moein A, Langenhorst J, Ribbing J, Zhang R, Tang M, Oh YS, Zhang W.
Exposure-Response Analysis of Etrolizumab in Patients with Moderately-to-severely Active Ulcerative Colitis
Pharmetheus Affiliates
Svensson RJ, Ribbing J, Kotani N, Dolton M, Vadhavkar S, Cheung D, Staton T, Choy DF, Putnam W, Jin J, Budha N, Karlsson MO, Quartino A, Zhu R.
Population Repeated Time-to-Event Analysis of Exacerbations in Asthma Patients: A Novel Approach for Predicting Asthma Exacerbations Based on Biomarkers, Spirometry, and Diaries/Questionnaires
Pharmetheus Affiliates
Faelens R, Luyckx N, Leirens Q, Bouillon T, Kuypers D, Annaert P.
Building Model-Informed Precision Dosing Software Using R: Blueprint for a State-of-the-Art Development Process
Pharmetheus Affiliates
Noack A, Mogensen PK, Nyberg J, Ivaturi V.
Generalized FOCE with Pumas
Pharmetheus Affiliates
Zannoni S, Brekkan A, Smania G.
Investigating the Identifiability of One-Stage IVIVC Population Models for Extended-Release Dosage Forms
Pharmetheus Affiliates
Mezzalana E, Tomita Y, Hansson E, Mazuir F, Wellhagen G, Ooi QX, Kitamura A, Nemoto D, Bolze S.
Population Pharmacokinetic Modelling and Simulation of Imeglimin in Type 2 Diabetes Patients to Support Dose Recommendations to Patients with Renal Impairment
Pharmetheus Affiliates
Sou T, Hansson E, Bergstrand M, Callewaert F, Sousa RP, Sargentini L.
Caplacizumab Model-Based Dosing Recommendations In Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura
Pharmetheus Affiliates
Sjögren E, Tarning J, Jonsson EN.
Lumenfantrine Exposure in Malnourished Children: PBPK Modeling Applied for Predictions and Dose Adjustments
Pharmetheus Affiliates
Smania G, Jonsson EN.
Conditional Distribution Modeling for Covariates Simulation Using Classification and Regression Trees Methods
Pharmetheus Affiliates
Acharya C, Magnusson MO, Vajjah P, Zamacona M.
Population Pharmacokinetic and Exposure-Response Models for Dapirolizumab Pegol in Patients with Systemic Lupus Erythematosus
Pharmetheus Affiliates
Mats Magnusson, Ph.D.
Ibrahim MMA, Plan EL, Jönsson S, Chen C, Karlsson MO.
Enhancing Efficiency and Decision Quality in Parkinson’s Disease Drug Trials for LRRK2 Programs Using Item Response Modelling
Pharmetheus Affiliates
Svensson RJ, Henrich A, Bianzano S, Sarubbi D, Röshammar D, Beetz N.
The Population PKPD of Unacylated and Acylated Ghrelin Following Single Rising Doses of BI 1356225 in Healthy Subjects is Impacted by the Time Since Last Meal
Pharmetheus Affiliates
Sahota T, Bergstrand M, Milligan P, Zamuner S, Chen C, Fairman D.
Towards Industrialisation of Probability of Pharmacological Success (PoPS)
Pharmetheus Affiliates
Eckernäs E, Timmermann C, Röshammar D, Ashton M.
Population Pharmacokinetic/Pharmacodynamic Modelling of the Psychedelic Experience Induced by N,N-dimethyltryptamine
Pharmetheus Affiliates
Kanacher T, Michon I, Lindauer A, Mezzalana E, Dansirikul C, Veau C, Mantilla JDG, Nock V, Fleury A.
A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol and Caffeine
Pharmetheus Affiliates
Valenzuela B, Pérez-Ruixo JJ, Leirens Q, Ouwerkerk-Mahadevan S, Poggesi I.
Effect of Ponesimod Exposure on Total Lymphocyte Dynamics in Patients with Multiple Sclerosis
Pharmetheus Affiliates
Schmid U, Weber B, Sarr C, Freiwald M.
Exposure–Safety Analyses of Nintedanib in Patients with Chronic Fibrosing Interstitial Lung Disease
Pharmetheus Affiliates
Röshammar D, Huang F, Albisetti M, Bomgaars L, Chalmers E, Luciani M, Halton J, Mitchell LG, Bergstrand M, Ibrahim MMA, Joseph D, Tartakovsky I, Gropper S, Brueckmann M, Brandão LR.
Pharmacokinetic Modeling and Simulation Support for Age‐ and Weight‐Adjusted Dosing of Dabigatran Etexilate in Children with Venous Thromboembolism
Pharmetheus Affiliates
Smania G, Jonsson EN.
Conditional Distribution Modeling as an Alternative Method for Covariates Simulation: Comparison with Joint Multivariate Normal and Bootstrap Techniques
Pharmetheus Affiliates
Schmid U, Weber B, Magnusson MO, Freiwald M.
Exposure-Efficacy Analyses of Nintedanib in Patients with Chronic Fibrosing Interstitial Lung Disease
Pharmetheus Affiliates
Ljungberg A, Segelsjö M, Dahlman P, Helenius M, Magnusson MO, Magnusson A.
Comparison of Quality of Urinary Bladder Filling in CT Urography with Different Doses of Furosemide in the Work-Up of Patients with Macroscopic Hematuria
Pharmetheus Affiliates
Sjögren E, Tarning J, Barnes KI, Jonsson EN.
A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children
Pharmetheus Affiliates
2020
Kanacher T, Lindauer A, Mezzalana E, Michon I, Veau C, Mantilla JD, Nock V, Ivaturi V.
A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine
Pharmetheus Affiliates
Anziano RJ, Milligan P.
Model Informed Drug Development: Collaboration Through A Common Framework
Pharmetheus Affiliates
Svensson RJ, Ribbing J, Kotani N, Dolton M, Vadhavkar S, Cheung D, Staton T, Choy DF, Putnam W, Jin J, Budha N, Karlsson MO, Quartino A, Zhu R.
Population RTTE Analysis of Exacerbations in Asthma Patients: a Novel Approach for Predicting Asthma Exacerbations Based on Biomarkers, Spirometry and Diaries/Questionnaires
Pharmetheus Affiliates
Langenhorst JB, Boss J, van Kesteren C, Lalmohamed A, Kuball J, Egberts ACG, Boelens JJ, Huitema ADR, van Maarseveen EM.
A Semi-Mechanistic Model Based on Glutathione Depletion to Describe Intra-Individual Reduction in Busulfan Clearance
Pharmetheus Affiliates
Roeshammar D, Huang F, Albisetti M, Bomgaars L, Chalmers E, Luciani M, Halton J, Mitchell L, Joseph D, Tartakovsky I, Gropper S, Reilly P, Brueckmann M, Brandão L, on Behalf of the Study Investigators.
Pharmacokinetic Modelling and Simulation Support the Age and Body-Weight-Adjusted Dosing of Dabigatran Etexilate in Paediatric Patients with Venous Thromboembolism, PB1271
Pharmetheus Affiliates
Langenhorst JB, Dorlo TPC, van Kesteren C, van Maarseveen E, Nierkens S, de Witte MA, Boelens JJ, Huitema ADR.
Clinical Trial Simulation To Optimize Trial Design for Fludarabine Dosing Strategies in Allogeneic Hematopoietic Cell Transplantation
Pharmetheus Affiliates
Mitra A, Suarez-Sharp S, Pepin XJH, Flanagan T, Zhao Y, Kotzagiorgis E, Parrott N, Sharan S, Tistaert C, Heimbach T, Zolnik B, Sjögren E, Wu F, Anand O, Kakar S, Li M, Veerasingham S, Kijima S, Lima Santos GM, Ning B, Raines K, Rullo G, Mandula H, Delvadia P, Dressman J, Dickinson PA, Babiskin A.
Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report
Pharmetheus Affiliates
Pepin X, Dressman J, Parrott N, Delvadia P, Mitra A, Zhang X, Babiskin A, Kolhatkar V, Seo P, Taylor L, Sjögren E, Butler J, Kostewicz E, Tannergren C, Koziolek M, Kesisoglou F, Dallmann A, Zhao Y, Suarez-Sharp S.
In Vitro Biopredictive Methods: A Workshop Summary Report
Pharmetheus Affiliates
2019
Lippert J, Burghaus R, Edginton A, Frechen S, Karlsson M, Kovar A, Lehr T, Milligan P, Nock V, Ramusovic S, Riggs M, Schaller S, Schlender J, Schmidt S, Sevestre M, Sjögren E, Solodenko J, Staab A, Teutonico D.
Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences
Pharmetheus Affiliates
Schoemaker R, Nayak S, Harnisch LO, Karlsson MO, on behalf of VISTA-ICH Collaboration.
Modeling and Simulation of the Modified Rankin Scale and National Institutes of Health Stroke Scale Neurological Endpoints in Intracerebral Hemorrhage
Pharmetheus Affiliates
Heimbach T, Suarez-Sharp S, Kakhi M, Holmstock N, Olivares-Morales A, Pepin X, Sjögren E, Tsakalozou E, Seo P, Li M, Zhang X, Lin HP, Montague T, Mitra A, Morris D, Patel N, Kesisoglou F.
Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report
Pharmetheus Affiliates
Brekkan A, Lopez-Lazaro L, Plan EL, Nyberg J, Kankanwadi S, Karlsson MO.
Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies
Pharmetheus Affiliates
Nyberg J, Jonsson EN, Karlsson MO, Häggström J, members of the HBGDki Community.
Properties of the Full Random Effect Modelling Approach With Missing Covariates
Pharmetheus Affiliates
Sargentini L, Hansson E, Bergstrand M, Callewaert F, Sousa RP.
Effect of Plasma Exchange on the Pharmacokinetics and Pharmacodynamics of Caplacizumab, PS1487
Pharmetheus Affiliates
Sargentini L, Hansson E, Bergstrand M, Callewaert F, Sousa RP.
Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients with Acquired Thrombotic Thrombocytopenic Purpura, PB2249
Pharmetheus Affiliates
Bergstrand M, Hansson E, Sargentini-Maier ML.
Caplacizumab Dosing Rational in aTTP Patients Supported by Mechanism Based PKPD Modelling
Pharmetheus Affiliates
Kristoffersson A, Röshammar D, Plan EL.
Assessment of Expected Drug Exposure Relative Maximum Safety Limits in Early Phase Studies
Pharmetheus Affiliates
Brekkan A, Lopez-Lazaro L, Plan EL, Acharya C, Yngman G, Nyberg J, Hooker AC, Kankanwadi S, Karlsson MO.
Model Based Support to Biosimilarity Assessment Planning – A Case Study of Pegfilgrastim
Pharmetheus Affiliates
Nyberg J, Karlsson MO, Jonsson EN.
Implicit and Efficient Handling of Missing Covariate Information Using Full Random Effects Modelling
Pharmetheus Affiliates
Sjögren E, Jonsson EN.
A PBPK Framework to Predict Drug Exposure in Malnourished Children
Pharmetheus Affiliates
Sarr C, Magnusson MO, Vajjah P, Zamacona M.
Population PK and PASI Exposure-Response Modelling for Certolizumab Pegol in Patients with Chronic Plaque Psoriasis
Pharmetheus Affiliates
Mats Magnusson, Ph.D.
Ibrahim MMA, de Mello VD, Uusitupa M, Tuomilehto J, Lindström J, Kjellsson MC, Karlsson MO.
Competing Risks Analysis of the Finnish Diabetes Prevention Study
Pharmetheus Affiliates
Netterberg I, Li CC, Molinero L, Budha N, Sukumaran S, Stroh M, Jonsson EN, Friberg LE.
A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients
Pharmetheus Affiliates
2018
Guiastrennec B, Sonne DP, Bergstrand M, Vilsbøll T, Knop FK, Karlsson MO.
Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans
Pharmetheus Affiliates
Terranova N, Smith MK, Nordgren R, Comets E, Lavielle M, Harling K, Hooker AC, Sarr C, Mentré F, Yvon F, Swat MJ.
The Standard Output: A Tool-Agnostic Modeling Storage Format
Pharmetheus Affiliates
Suarez-Sharp S, Cohen M, Kesisoglou F, Abend A, Marroum P, Delvadia P, Kotzagiorgis E, Li M, Nordmark A, Bandi N, Sjögren E, Babiskin A, Heimbach T, Kijima S, Mandula H, Raines K, Seo P, Zhang X.
Applications of Clinically Relevant Dissolution Testing: Workshop Summary Report
Pharmetheus Affiliates
Brekkan A, Lopez-Lazaro L, Yngman G, Plan EL, Acharya C, Hooker AC, Kankanwadi S, Karlsson MO.
A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
Pharmetheus Affiliates
Jonsson EN, Harling K.
Increasing the Efficiency of the Covariate Search Algorithm in the SCM
Pharmetheus Affiliates
Kantasiripitak W, Sjögren E, Magnusson MO.
Bridging Physiologically Based Pharmacokinetic (PBPK) and Population Pharmacokinetic (PopPK) Analyses in Paediatric Drug Development: A Case Study Based on Intravenous Esomeprazole
Pharmetheus Affiliates
Mats Magnusson, Ph.D.
Kloprogge F, Workman L, Borrman S, Tékété M, Lefèvre G, Hamed K, Piola P, Ursing J, Kofoed PE, Mårtensson A, Ngasala B, Björkman A, Ashton M, Friberg Hietala S, Francesca A, Parikh S, Mwai L, Davis TME, Karunajeewa HA, Salman S, Checchi F, Fogg C, Newton PN, Mayxay M, Deloron P, Faucher JF, Nosten F, Ashley EA, McGready R, van Vugt M, Proux P, Price RN, Karbwang J.
Artemether-Lumefantrine Dosing for Malaria Treatment in Young Children and Pregnant Women: A Pharmacokinetic-Pharmacodynamic Meta-Analysis
Pharmetheus Affiliates
Rasmussen CH, Smith MK, Ito K, Sundararajan V, Magnusson MO, Jonsson NE, Fostvedt L, Burger P, McFadyen L, Tensfeldt TG, Nicholas T.
PharmTeX: a LaTeX-Based Open-Source Platform for Automated Reporting Workflow
Pharmetheus Affiliates
Mats Magnusson, Ph.D.
2017
Dosne AG, Bergstrand M, Karlsson MO.
An Automated Sampling Importance Resampling Procedure for Estimating Parameter Uncertainty
Pharmetheus Affiliates
Conrado DJ, Karlsson MO, Romero K, Sarr C, Wilkins JJ.
Open Innovation: Towards Sharing of Data, Models and Workflows
Pharmetheus Affiliates
Friberg Hietala S, Manolis E, Musuamba FT.
A Regulatory View on Dose Finding Studies and on the Value of Dose-Exposure-Response Analysis
In O’Quigley J, Iasonos A, Bornkamp B, (Eds), Handbook of Methods for Designing, Monitoring, and Analyzing Dose-Finding Trials. Boca Raton FL:CRC Press.
Pharmetheus Affiliates
Yngman G, Nyberg J, Jonsson EN, Karlsson MO.
Practical Considerations for Using the Full Random Effects Modeling (FREM) Approach to Covariate Modeling
Pharmetheus Affiliates
Hamrén B, Röshammar D, Nyberg J, Bergstrand M, Andersson T, Storey RF, Stanski D.
Pharmacokinetic and Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients with Prior Myocardial Infarction (PEGASUS-TIMI 54)
Pharmetheus Affiliates
Röshammar D, Nyberg J, Andersson T, Stanski D, Storey RF, Hamrén B.
Exposure-Response Analyses Supporting Ticagrelor Dosing Recommendation in Patients With Prior Myocardial Infarction
Pharmetheus Affiliates
Röshammar D, Bergstrand M, Andersson T, Storey RF, Hamrén B.
Population Pharmacokinetics of Ticagrelor and AR-C124910XX in Patients with Prior Myocardial Infarction
Pharmetheus Affiliates
Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, Russu A.
Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data
Pharmetheus Affiliates
Magnusson MO, Samtani MN, Plan EL, Jonsson EN, Rossenu S, Vermeulen A, Russu A.
Population Pharmacokinetics of a Novel Once-Every 3 Months Intramuscular Formulation of Paliperidone Palmitate in Patients with Schizophrenia
Pharmetheus Affiliates
Nguyen THT, Mouksassi M-S, Holford N, Al-Huniti N, Freedman I, Hooker AC, John J, Karlsson MO, Mould DR, Pérez-Ruixo JJ, Plan EL, Savic R, van Hasselt JGC, Weber B, Zhou C, Comets E, Mentré F, for the Model Evaluation Group of the International Society of Pharmacometrics (ISoP) Best Practice Committee.
Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics
Pharmetheus Affiliates
Dosne AG, Bergstrand M, Karlsson MO.
An Automated Sampling Importance Resampling Procedure for Estimating Parameter Uncertainty
Pharmetheus Affiliates
2016
Slejko JF, Willke RJ, Ribbing J, Milligan P.
Translating Pharmacometrics to a Pharmacoeconomic Model of COPD
Pharmetheus Affiliates
Magnusson MO.
Application of a Multi-Criteria Decision Analysis Model in the Dose Selection of Combination Therapy for Overactive Bladder
Pharmetheus Affiliates
Mats Magnusson, Ph.D.
Jonsson EN, Nyberg J, Häggström J, Lifecycle Auxology & Neurocognitive Development team, representing the Healthy Birth, Growth and Development knowledge integration (HBGDki) community.
Determinants for Physical Growth Patterns in Low- and Middle-Income Countries
Pharmetheus Affiliates
Magnusson MO, Plan EL, Remy A, König M, Aigner S, Braun V, Zipp D, Zhou X, Wolter R, Schüttrumpf J, Wartenberg-Demand A, Dälken B, Rharbaoui F.
Population PKPD Analysis of CD4 and ACR Response after SC Administration of Tregalizumab to Patients with Rheumatoid Arthritis
Pharmetheus Affiliates
Mats Magnusson, Ph.D.
Magnusson MO, Jonsson EN.
Reproducible Reporting
Pharmetheus Affiliates
Mats Magnusson, Ph.D.
Mazzei P, Mezzalana E, Smania G, Jonsson EN, Jönsson S, Bouchene S, Karlsson MO, Scartoni S, Capriati A.
Population Exposure-Response Modeling of Oral Nepadutant Administration in Infants with Colic
Pharmetheus Affiliates
Schoemaker R, Nayak S, Denney WS, Jonsson EN, Karlsson MO, Harnisch LO, on behalf of the VISTA-ICH Collaborators.
Modelling and Simulation of Neurological Endpoints (Modified Rankin Scale [mRS] and National Institute of Health Stroke Scale [NIHSS]) to Aid Clinical Trial Design in Intracerebral Hemorrhage (ICH)
Pharmetheus Affiliates
Ribbing J, Korell J, Cerasoli F, Milligan P, Martin SW, Karlsson MO.
Predicting Reductions in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations from FEV1 – A Model-Based Meta-Analysis of Literature Data from Controlled Randomized Clinical Trials
Pharmetheus Affiliates
Van Schaick E, Benninga MA, Levine A, Magnusson MO, Troy S.
Development of a Population Pharmacokinetic Model of Prucalopride in Children with Functional Constipation
Pharmetheus Affiliates
Mats Magnusson, Ph.D.
Jonsson EN, Xie R, Marshall SF, Arends RH.
Population Pharmacokinetics of Tanezumab in Phase 3 Clinical Trials for Osteoarthritis Pain
Pharmetheus Affiliates
Korell J, Martin SW, Karlsson MO, Ribbing J.
A Model-Based Longitudinal Meta-Analysis of FEV1 in Randomized COPD Trials
Pharmetheus Affiliates
2015
Norberg Å, Pauline Koch, Kanes SJ, Björnsson MA, Barassin S, Ahlén K, Kalman S.
A Bolus and Bolus Followed by Infusion Study of AZD3043, an Investigational Intravenous Drug for Sedation and Anesthesia: Safety and Pharmacodynamics in Healthy Male and Female Volunteers
Pharmetheus Affiliates
Khariton T, Jonsson EN, Bergstrand M, Carrothers TJ, Ghahramani P.
Population Pharmacokinetic (PPK) Modeling of Vilazodone in Adolescent Patients with Major Depressive Disorder (MDD)
Pharmetheus Affiliates
